

6. Simoni RD, Hill RL, Vaughan M. The discovery of insulin: the work of Frederick Banting and Charles Best. *J Biol Chem.* 2002;277(26):e1-e2.
7. Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. *Biotechnol J.* 2008;3(1):90-97.
8. Zaykov AN, Mayer JP, DiMarchi RD. Pursuit of a perfect insulin. *Nat Rev Drug Discov.* 2016;15(6):425-439.
9. Kang S, Brange J, Burch A, et al. Subcutaneous insulin absorption explained by insulin's physicochemical properties: evidence from absorption studies of soluble human insulin and insulin analogues in humans. *Diabetes Care.* 1991;14(11):942-948.
10. Cheng R, Taleb N, Stainforth-Dubois M, et al. The promising future of insulin therapy in diabetes mellitus. *Am J Physiol Endocrinol Metab.* 2021;320(5):E886-E890.
11. Howey DC. A rapidly absorbed analogue of human insulin. *Diabetes.* 1994;43:396-402.
12. Hirsch IB, Juneja R, Beals JM, et al. The evolution of insulin and how it informs therapy and treatment choices. *Endocr Rev.* 2020;41(5):733-755.
13. Heise T, Hövelmann U, Brøndsted L, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. *Diabetes Obes Metab.* 2015;17(7):682-688.
14. Andersen G, Meiffren G, Lamers D, et al. Ultra-rapid Bio-Chaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. *Diabetes Obes Metab.* 2018;20(11):2627-2632.
15. Hagedorn HC, Jensen BN, Krarup NB, et al. Protamine insulin. *JAMA.* 1936;106(3):177-180.
16. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. *Diabetes Care.* 2003;26(5):1490-1496.
17. Bolli GB, Owens DR. Insulin glargine. *Lancet.* 2000;356(9228):443-445.
18. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. *Pharm Res.* 2004;21(8):1498-1504.
19. Becker RHA, Dahmen R, Bergmann K, et al. New insulin glargine 300 units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/mL. *Diabetes Care.* 2015;38(4):637-643.
20. Freemantle N, Chou E, Frois C, et al. Safety and efficacy of insulin glargine 300 U/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. *BMJ Open.* 2016;6(2):e009421.
21. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. *Diabetes Metab Syndr Obes.* 2012;5:191-204.
22. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet.* 2012;379(9825):1489-1497.
23. Rosenstock J, Juneja R, Beals JM, et al. The basis for weekly insulin therapy: evolving evidence with insulin icodex and insulin efsitora alfa. *Endocr Rev.* 2024;45(3):379-413.
24. Oleck J, Kassam S, Goldman JD. Commentary: why was inhaled insulin a failure in the market? *Diabetes Spectr.* 2016;29(3):180-184.
25. Bakh NA, Bisker G, Lee MA, et al. Rational Design of Glucose-Responsive Insulin Using Pharmacokinetic Modeling. *Adv Healthc Mater.* 2017;6(22):1700601.
26. Subramanian S, Khan F, Hirsch IB. New advances in type 1 diabetes. *BMJ.* 2024;384.
27. Teo E, Hassan N, Tam W, et al. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. *Diabetologia.* 2022;65(4):604-619.
28. American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes – 2026. *Diabetes Care.* 2026;49(Suppl 1):S150.
29. Ware J, Hovorka R. Recent advances in closed-loop insulin delivery. *Metabolism.* 2022;127:154953.
30. Klonoff DC, Kerr D. Smart pens will improve insulin therapy. *J Diabetes Sci Technol.* 2018;12(3):551-553.
31. American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes – 2026. *Diabetes Care.* 2026;49(Suppl 1):S132-S149.
32. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2019;104(5):1520-1574.
33. Kudva YC, Henderson RJ, Kanapka LG, et al. Automated insulin delivery in older adults with type 1 diabetes. *NEJM Evid.* 2025;4(1):EVID02400200.

ON-LINE KURZ

Současný pohled na využití NSA v muskuloskeletální bolesti: role kombinace *naproxen-esomeprazol*

OBSAH KURZU

- 1. Současný pohled na využití NSA a kombinaci analgetik v léčbě muskuloskeletální bolesti – MUDr. Marek Hák, Ph.D.
- 2. Fixní kombinace naproxenu a esomeprazolu – novinka v léčbě bolesti u revmatických onemocnění – MUDr. Marta Olejárová, CSc.
- 3. Místo naproxenu mezi ostatními nesteroidními antirevmatiky používanými v léčbě bolesti a zánětu u nejčastějších revmatických chorob – prof. MUDr. Pavel Horák, CSc.
- 4. Léčba chronické bolesti – MUDr. Marek Hák, Ph.D.

ODBORNÝ GARANT:

MUDr. Pavel Rutar

Interní oddělení, FN Motol a Homolka v Praze

POŘADATEL:

SOLEN, s. r. o., ve spolupráci s Interním oddělením, FN Motol a Homolka v Praze

POČET
KREDITŮ **2**Registrace
ZDARMATERMÍN
březen 2026
až únor 2027
dostupný na
online.solen.cz

PARTNER

PharmaSwiss
Choose More Life

BAUSCH Health

